BOC Sciences Announces Featured PROTAC Design Services to Meet New Drug Discovery Goals

BOC Sciences announced featured PROTAC design services to customers around the world to meet new drug discovery goals.

Chemical Synthesis of Peptide Drug with Solid-Phase Methodology

Peptide plays a key role in basic biochemical and physiological processes, and it is essential to many aspects of biomedical research, especially when the pharmaceutical industry continues to apply new drug candidates in the biological field. Therefore, rapid, efficient, and reliable methodology for the chemical synthesis of peptide drugs is of utmost interest in chemical biology research.

Total Peptide Library: More Flexible and Productive

Since the peptide library provides a powerful tool for drug development, protein-protein interactions, and other biochemical as well as pharmaceutical applications, the total peptide library becomes a productive tool as it enjoys higher stability because of the special structure of the peptide bond. Additionally, its construction cycle is relatively short compared with traditional peptide library construction technologies, accelerating the development of peptides drugs.

New programme celebrates ChargePoint Technology's role in COVID-19 vaccine rollout

New Release of Genedata Imagence Advances AI-powered HCS Image Analysis

Genedata Imagence 5.0 industrializes the analysis of imaging assays across R&D organizations with advanced data QC workflows and scalable, flexible deployment options.

New BHM® Anti-Viral Nasal Spray launches in Singapore

Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, today announces the Singapore launch of its latest technology, BHM® Anti-Viral Nasal Spray, an easy-to-use nasal device with a unique patented formulation, Norizite™, designed to help prevent infection from the inhalation of airborne viruses within the nasal passages. The product will be available in Singapore from 1st May.

AARDEX® Group adds etectRx to their MEMS® Adherence Hardware ecosystem

AARDEX® Group adds etectRx to their MEMS® Adherence Hardware ecosystem The partnership sees the integration of AARDEX’s adherence analytics software with etectRx’s ingestible adherence sensor Liege, Belgium (APRIL 28th, 2022) – Belgium-based AARDEX® Group, the leader in measuring and managing medication adherence in clinical trials today announced a strategic partnership with etectRx, Inc. This new collaboration combines etectRx’s ingestible event marker, the ID-Cap™ System, and AARDEX® Group’s MEMS® Adherence Software (MEMS AS®) to track medication-taking behaviors. Together, they provide a holistic, objective, and precise method to measure and manage adherence to solid form dose medications.

Royal seal of approval for Wales-based resin manufacturer Purolite

Purolite, an Ecolab company and leading manufacturer of synthetic and agarose-based resins used in the bioprocessing industry, has been awarded the prestigious Queen’s Award for Enterprise in the International Trade category.

CD Formulation Enriches Its Supply of Active Pharmaceutical Ingredient Excipients

Continuing to be a trust-worthy CRO company for drug formulation and development, CD Formulation recently announces the enrichment of its active pharmaceutical ingredient excipient offerings. Now a number of API excipients are readily obtainable at CD Formulation, including Cetrorelix Acetate, Fondaparinux Sodium, Calcitriol, Vitamine D3, Tirofiban Hydrochloride, Eptifibatide, Ferric Ammonium Citrate, Calcipotriol API, Calcium Orotate, Meglumine, Obeticholic Acid, Potassium Magnesium Citrate and Magnesium Oxide.

Adsorptive Polymers Are Now Available at Alfa Chemistry for Applications in Water Treatment, Medicine, Health Care, and Machine Processing

Alfa Chemistry Launches Heat Stabilizers for PVC Industry

Biopharma PEG Develops PEG Derivatives for ADCs Development

Biopharma PEG leapts at the opportunity to develop various high purity PEG derivatives used as ADC linkers.

1upHealth Unveils Data Conversion App.

Good afternoon, all -- 1upHealth, an intelligent health data platform with over 10,000 clinical and payer endpoints, today unveiled SQL on FHIR to streamline access to and make FHIR healthcare data computable to help organizations discover analytical insights and create compelling visualizations. SQL on FHIR allows healthcare organizations to convert FHIR data into a form that is easily searchable for specifics such as a patient’s observations, vital signs, and smoking status. This new platform is the next phase of 1upHealth’s mission to solve healthcare’s biggest data challenges, including helping organizations convert legacy claims and clinical data into clean, uniform FHIR. If interested in learning more about SQL on FHIR, I am happy to connect you with FHIR expert Joe Gagnon, CEO of 1upHealth, and/or a health plan executive to discuss the following: • Why SQL on FHIR fills the market gap for data conversion and will further aid healthcare organizations to perform at their highest levels • Strategies for organizations to enable FHIR analytics to reduce cost and improve operating models, quality metrics, and outcomes • The urgency to convert FHIR into searchable metrics with interoperability regulations looming and how this will help organizations further track and improve population health and SDoH The full release is included above. Please let me know if you have any questions or requests. Thanks! Anisa

Samsung Biologics Reports First Quarter 2022 Financial Results

CD ComputaBio Unveils Protein Structure Modeling Service for Drug Development

Untargeted Lipidomics Now Available with Creative Proteomics’s New Cutting-Edge Lipidomics Platform

Pronalyse Unveils Gene Therapy Products Characterization Service to Safely Accelerate Drug Development

Creative Proteomics Metabolomics Expands Service Offering with the Launch of Plant Untargeted Metabolomics Service

Global Biologics CDMO Market is set to witness a CAGR of 15% to reach $35 billion by 2025, driven by the growing biopharmaceutical end market

Rapidly expanding pipelines of cell & gene therapies and new vaccines and significant VC fundings are driving the growth of the Biologics CDMO market.

Biofourmis Receives Significant Growth Investment from General Atlantic to Propel Company to Unicorn Status

With this investment, Biofourmis plans to scale up its virtual care offerings. This includes delivering personalized and predictive in-home care to a growing number of acutely ill patients and expanding its recently announced virtual specialty care services, Biofourmis Care, to those patients with complex chronic conditions. In parallel, Biofourmis plans to fund clinical trials to advance the development of digital therapies that work in conjunction with high-value drugs to improve efficacy, while forming strategic partnerships with companies in the digital health and virtual-first care ecosystems.